TrialThe Lancet. Infectious diseases2022

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

Alasdair P S Munro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.